HER2 as a Promising Target for Cytotoxicity T Cells in Human Melanoma Therapy

Ma, Juan; Han, Houxiang; Liu, Deruo; Li, Wei; Feng, Hao; Xue, Xin; Wu, Xiaogang; Niu, Ge; Zhang, Ge; Zhao, Yunfeng; Liu, Changzhen; Tao, Hua; Gao, Bin

doi:10.1371/journal.pone.0073261

Cited by 28 publications

(35 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…179 HER2/neu, an antibody commonly used to treat breast cancers, has recently shown positive effect on a number of melanoma cell lines and xenograft models. 180 Bevacizumab, an anti-VEGF antibody, given to metastatic melanoma patients in combination with albumin-bound paclitaxel and carboplatin, resulted in an increase of CD8+ lymphocytes but did not affect the Th1/Th2 ratio. 181 …”

Section: Reversing Tolerance In Melanomamentioning

confidence: 97%

Immunomodulatory Effects of Sex Hormones: Requirements for Pregnancy and Relevance in Melanoma

Enninga

Holtan

Creedon

et al. 2014

Mayo Clinic Proceedings

View full text Add to dashboard Cite

Similarities between the pathologic progression of cancer and the physiologic process of placentation (e.g., proliferation, invasion, and local/systemic tolerance) have been recognized for many years. Sex hormones such as human chorionic gonadotropin, estrogens, progesterone, and others contribute to induction of immunologic tolerance at the beginning of gestation. Sex hormones have been shown to play contributory roles in the growth of cancers such as breast, prostrate, endometrial and ovarian cancer, but their involvement as putative mediators of the immunologic escape of cancer are still being elucidated. Herein, we compare the emerging mechanism by which sex hormones modulate systemic immunity in pregnancy and their potentially similar role in cancer. To do this, we conducted a PubMed search using combinations of the following key words: immune regulation, sex hormones, pregnancy, melanoma and cancer. We did not limit our search to specific publication dates. Mimicking the maternal immune response to pregnancy, especially in late gestation, might aid in design of better therapies to reconstitute endogenous anti-tumor immunity and improve survival.

show abstract

Section: Reversing Tolerance In Melanomamentioning

confidence: 97%

Immunomodulatory Effects of Sex Hormones: Requirements for Pregnancy and Relevance in Melanoma

Enninga

Holtan

Creedon

et al. 2014

Mayo Clinic Proceedings

View full text Add to dashboard Cite

show abstract

“…One is luciferase quantitative assay. [28][29][30][31][32] The other is collecting cell free supernatants, and the cytotoxicity was mostly measured with Lactate dehydrogenase activity kit (Sigma-Aldrich, St. Louis, MO, USA).…”

Section: Cytotoxicity Assaymentioning

confidence: 99%

“…According to the data provided by the literature, 21,[28][29][30] 150 ng/10 6 cells was chosen as the concentration of B7-H3Bi-Ab, ATC mixed with OKT3 and anti-B7-H3 mAb were used as unarmed ATC controls. Both were interacted at 37°C for 18 hours.…”

Section: Cytotoxicity Effects Of B7-h3bi-abarmed Atc On Bladder Canmentioning

confidence: 99%

Targeting immunotherapy for bladder cancer using anti‐CD3× B7‐H3 bispecific antibody

et al. 2018

Cancer Medicine

Self Cite

View full text Add to dashboard Cite

ObjectiveB7‐H3 is attractive for cancer immunotherapy with B7‐H3 overexpressed tumors. To explore whether B7‐H3 is an effective target for patients with bladder cancer, anti‐CD3× anti‐B7‐H3 bispecific antibodies (B7‐H3Bi‐Ab) was armed with activated T cells (ATC) to kill bladder cancer cells.MethodsHigh expressions of B7‐H3 on human bladder cancer cells were detected, including Pumc‐91 and T24 cells, and their chemotherapeutic drug‐resistant counterparts. ATC generated from healthy donors were stimulated with anti‐CD3 monoclonal antibody and interleukin‐2 (IL‐2) for 13 days. The ability of ATC armed with B7‐H3Bi‐Ab to kill bladder cancer cells was detected by flow cytometry, LDH, Elisa, and luciferase quantitative assay. Moreover, ATC generated from bladder cancer patients was armed with B7‐H3Bi‐Ab to verity the cell killing by the methods as previously described.ResultsCompared with unarmed ATC, a significant increased cytotoxicity of B7‐H3Bi‐Ab‐armed ATC against bladder cancer cells was discovered. The B7‐H3Bi‐Ab‐armed ATC secreted more IFN‐γ, TNF‐α, and expressed high levels of activation marker CD69. Interestingly, despite the presence of immunosuppression in patients and resistance in chemotherapeutic drug‐resistant cancer cell lines, B7‐H3Bi‐Ab‐armed ATC from patients with bladder cancer still showed significant cytotoxic activity against bladder cancer cells and their chemotherapeutic drug‐resistant counterparts.ConclusionB7‐H3 is an effective target for bladder cancer. B7‐H3Bi‐Ab enhances the ability of ATC to kill bladder cancer cells. B7‐H3Bi‐Ab‐armed ATC is promisingly to provide a novel strategy for current bladder cancer therapy.

show abstract

“…Luciferase quantitative assay, a simple and sensitive method, has been increasingly and widely used to measure the cytolytic effects of various effector cells (36)(37)(38). In the present study, we used this method to test the cytotoxicity of stimulated cells against K562-luc cells.…”

Section: Expanded Nk Cells Were Effectively Activated Through Immobilmentioning

confidence: 99%

Expansion of NK cells from PBMCs using immobilized 4-1BBL and interleukin-21

Liu

et al. 2015

International Journal of Oncology

Self Cite

View full text Add to dashboard Cite

Abstract. Adoptive transfer of NK cells has been widely applied clinically for cancer immunotherapy. However, the difficulties to obtain a large number of activated NK cells impede the successful application of such therapy. In the present study, we implemented a novel method involving the use of immobilized human 4-1BBL and interleukin-21 to amplify NK cells from the peripheral blood mononuclear cells (PBMCs) of healthy donors. Following stimulation for 21 days, we achieved considerable expansion of NK cells with high purity and strong cytotoxicity. This is the first time solid phase cytokines were used to augment NK cells, and this method has the advantage of no need to introduce feeder cells, without prior purification of NK cells and it effectively stimulated and expanded NK cells. The strategy of cell proliferation and activation could lead to a safer and more effective application of NK cells clinically.

show abstract

HER2 as a Promising Target for Cytotoxicity T Cells in Human Melanoma Therapy

Cited by 28 publications

References 30 publications

Immunomodulatory Effects of Sex Hormones: Requirements for Pregnancy and Relevance in Melanoma

Immunomodulatory Effects of Sex Hormones: Requirements for Pregnancy and Relevance in Melanoma

Targeting immunotherapy for bladder cancer using anti‐CD3× B7‐H3 bispecific antibody

Expansion of NK cells from PBMCs using immobilized 4-1BBL and interleukin-21

Contact Info

Product

Resources

About